| |
|
|
|
|
|
Turbidimetric test for the measurement of Apo A1 in human serum or plasma. Anti- Apo A1 antibodies when mixed with samples containing Apo A1, form insoluble complexes. These complexes cause an absorbance change, dependent upon the Apo A1 concentration of the patient sample, that can be quantified by comparison from a calibrator of know Apo A1 concentration.
|
Company:
Date:
December 14, 2008
|
|
|
|
|
|
|
|
|
|
Serum matrix, 0.45 µm filtered. Concentration by nephelometric assay.
|
Company:
Date:
December 14, 2008
|
|
|
|
|
|
|
|
|
|
Serum matrix, 0.45 µm filtered. Concentration by nephelometric assay.
|
Company:
Date:
December 14, 2008
|
|
|
|
|
|
|
|
|
|
Serum matrix, 0.2 µm filtered. Concentration by nephelometric assay.
|
Company:
Date:
December 14, 2008
|
|
|
|
|
|
|
|
|
|
Turbidimetric test for the measurement of Apo B in human serum or plasma.
Anti- Apo B antibodies when mixed with samples containing Apo B, form insoluble complexes. These complexes cause an absorbance change, dependent upon the Apo B concentration of the patient sample, that can be quantified by comparison from a calibrator of know Apo B concentration
|
Company:
Date:
December 14, 2008
|
|
|
|
|
|
|
|
|
|
Serum matrix, 0.2 µm filtered. Concentration by nephelometric assay.
|
Company:
Date:
December 14, 2008
|
|
|
|
|
|
|
|
|
|
Serum matrix, 0.2 µm filtered. Concentration by nephelometric assay.
|
Company:
Date:
December 14, 2008
|
|
|
|
|
|
|
|
|
|
Serum matrix, 0.2 µm filtered. Concentration by nephelometric assay.
|
Company:
Date:
December 14, 2008
|
|
|
|
|
|
|
|
|
|
Turbidimetric test for the measurement of Apolipoprotein C II in human serum or plasma. Anti- apo C II antibodies when mixed with samples containing Apo C II, form insoluble complexes. These complexes cause an absorbance change, dependent upon the Apo C II concentration of the patient sample, that can be quantified by comparison from a calibrator of know Apo C II concentration.
|
Company:
Date:
December 14, 2008
|
|
|
|
|
|
|
|
|
|
Turbidimetric test for the measurement of Apolipoprotein C III in human serum or plasma. Anti- apo C III antibodies when mixed with samples containing Apo C III, form insoluble complexes. These complexes cause an absorbance change, dependent upon the Apo C III concentration of the patient sample, that can be quantified by comparison from a calibrator of know Apo C III concentration.
|
Company:
Date:
December 14, 2008
|
|
|
|
|
|